Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Inventory (2021 - 2025)

Mirum Pharmaceuticals has reported Inventory over the past 5 years, most recently at $24.9 million for Q4 2025.

  • Quarterly results put Inventory at $24.9 million for Q4 2025, up 11.09% from a year ago — trailing twelve months through Dec 2025 was $24.9 million (up 11.09% YoY), and the annual figure for FY2025 was $24.9 million, up 11.09%.
  • Inventory for Q4 2025 was $24.9 million at Mirum Pharmaceuticals, up from $24.0 million in the prior quarter.
  • Over the last five years, Inventory for MIRM hit a ceiling of $24.9 million in Q4 2025 and a floor of $1.5 million in Q4 2021.
  • Median Inventory over the past 5 years was $21.6 million (2024), compared with a mean of $15.3 million.
  • Biggest five-year swings in Inventory: surged 318.54% in 2023 and later dropped 2.95% in 2024.
  • Mirum Pharmaceuticals' Inventory stood at $1.5 million in 2021, then skyrocketed by 267.81% to $5.6 million in 2022, then skyrocketed by 300.93% to $22.3 million in 2023, then grew by 0.41% to $22.4 million in 2024, then increased by 11.09% to $24.9 million in 2025.
  • The last three reported values for Inventory were $24.9 million (Q4 2025), $24.0 million (Q3 2025), and $22.9 million (Q2 2025) per Business Quant data.